{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:22:10Z","timestamp":1761823330678,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["30570641","30870841"],"award-info":[{"award-number":["30570641","30870841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.jneuroim.2010.06.006","type":"journal-article","created":{"date-parts":[[2010,8,20]],"date-time":"2010-08-20T06:32:34Z","timestamp":1282285954000},"page":"35-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Selective recognition and elimination of nicotinic acetylcholine receptor-reactive B cells by a recombinant fusion protein AChR-Fc in myasthenia gravis in vitro"],"prefix":"10.1016","volume":"227","author":[{"given":"Ting","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2010.06.006_bib1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","article-title":"Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis","volume":"78","author":"Baek","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.06.006_bib2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/icb.2008.34","article-title":"Immune regulation: FcgammaRIIB-regulating the balance between protective and autoreactive immune responses","volume":"86","author":"Baerenwaldt","year":"2008","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12016-008-8114-x","article-title":"Recent advances in the treatment of systemic sclerosis","volume":"36","author":"Bournia","year":"2009","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pharmthera.2006.03.005","article-title":"B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target","volume":"112","author":"Dalakas","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200305000-00011","article-title":"The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets","volume":"15","author":"Dorner","year":"2003","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ncprheum0042","article-title":"B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus","volume":"2","author":"Eisenberg","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ni1151","article-title":"The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+anti-DNA plasma cells","volume":"6","author":"Fukuyama","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2008.11.006","article-title":"Use of rituximab in patients with systemic lupus erythematosus: an update","volume":"8","author":"Garcia-Carrasco","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.06.006_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mus.21047","article-title":"Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis","volume":"38","author":"Kerkeni","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.06.006_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jneuroim.2007.11.005","article-title":"Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis","volume":"194","author":"Li","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/intimm\/dxm133","article-title":"Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor","volume":"20","author":"Mihaylova","year":"2008","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2133.2000.03328.x","article-title":"Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris","volume":"142","author":"Proby","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2567.2004.01875.x","article-title":"Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen","volume":"112","author":"Reiners","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2010.06.006_bib19","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2165\/00003495-200666150-00004","article-title":"B-cell-targeted therapy for systemic lupus erythematosus","volume":"66","author":"Sabahi","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jneuroim.2010.06.006_bib20","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1002\/eji.200737143","article-title":"Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL\/lpr mice","volume":"37","author":"Tchorbanov","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1073\/pnas.79.1.188","article-title":"Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies","volume":"79","author":"Tzartos","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jneuroim.2010.06.006_bib23","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.4049\/jimmunol.134.4.2343","article-title":"Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera","volume":"134","author":"Tzartos","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib24","first-page":"18","article-title":"Experimental autoimmune myasthenia gravis in the mouse","author":"Wu","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib26","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.06.006_bib27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm0502-518","article-title":"A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation","volume":"8","author":"Zhu","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2010.06.006_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm1219","article-title":"A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation","volume":"11","author":"Zhu","year":"2005","journal-title":"Nat. Med."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572810002614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572810002614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:14:36Z","timestamp":1759047276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572810002614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":28,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0165572810002614"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2010.06.006","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective recognition and elimination of nicotinic acetylcholine receptor-reactive B cells by a recombinant fusion protein AChR-Fc in myasthenia gravis in vitro","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2010.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}